N J Brown

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Thromb Haemost 77:522-5. 1997
  2. ncbi request reprint Aldosterone and PAI-1: implications for renal injury
    Nancy J Brown
    Deaprtment of Medicine, Vanderbilt University, Nashville, TN, USA
    J Nephrol 15:230-5. 2002
  3. ncbi request reprint ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 40:859-65. 2002
  4. ncbi request reprint The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease
    Nancy J Brown
    Divisions of Clinical Pharmacology and Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Semin Nephrol 22:399-406. 2002
  5. ncbi request reprint Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000
  6. ncbi request reprint Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Clin Endocrinol Metab 85:336-44. 2000
  7. ncbi request reprint Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville Veterans Administration Medical Center, Nashville, TN, USA
    Hypertension 34:285-90. 1999
  8. ncbi request reprint Bradykinin stimulates tissue plasminogen activator release in human vasculature
    N J Brown
    Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville Veterans Administration Medical Center, Nashville, TN, USA
    Hypertension 33:1431-5. 1999
  9. ncbi request reprint Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
    N J Brown
    Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Hypertension 32:965-71. 1998
  10. ncbi request reprint Angiotensin-converting enzyme inhibitors
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 97:1411-20. 1998

Collaborators

Detail Information

Publications87

  1. ncbi request reprint Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Thromb Haemost 77:522-5. 1997
    ..Bradykinin had no effect on PAI-1 antigen levels. These in vivo data suggest that infusion of bradykinin results in an increase in circulating t-PA levels without an effect on PAI-1...
  2. ncbi request reprint Aldosterone and PAI-1: implications for renal injury
    Nancy J Brown
    Deaprtment of Medicine, Vanderbilt University, Nashville, TN, USA
    J Nephrol 15:230-5. 2002
    ..Aldosterone receptor antagonism decreases both PAI-1 expression and fibrosis in animal models. These findings have implications for the clinical management of cardiovascular and renal disease...
  3. ncbi request reprint ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 40:859-65. 2002
    ....
  4. ncbi request reprint The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease
    Nancy J Brown
    Divisions of Clinical Pharmacology and Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Semin Nephrol 22:399-406. 2002
    ..Interruption of the RAAS decreases both PAI-1 expression and fibrosis in animal models. These findings have implications for the clinical management of renal disease...
  5. ncbi request reprint Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000
    ....
  6. ncbi request reprint Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Clin Endocrinol Metab 85:336-44. 2000
    ..Taken together, these data support the hypothesis that aldosterone modulates the effect of Ang II on PAI-1 expression in vitro and in vivo in humans...
  7. ncbi request reprint Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville Veterans Administration Medical Center, Nashville, TN, USA
    Hypertension 34:285-90. 1999
    ..Further studies are needed to address the mechanism for the contrasting effects of these 2 classes of drugs on fibrinolysis and to define the clinical significance of these differences...
  8. ncbi request reprint Bradykinin stimulates tissue plasminogen activator release in human vasculature
    N J Brown
    Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville Veterans Administration Medical Center, Nashville, TN, USA
    Hypertension 33:1431-5. 1999
    ..These data demonstrate that bradykinin stimulates tPA release in the human vasculature...
  9. ncbi request reprint Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
    N J Brown
    Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Hypertension 32:965-71. 1998
    ..The data suggest that ACE inhibition has the potential to reduce the incidence of thrombotic cardiovascular events by blunting the morning peak in PAI-1...
  10. ncbi request reprint Angiotensin-converting enzyme inhibitors
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 97:1411-20. 1998
    ....
  11. ncbi request reprint Recurrent angiotensin-converting enzyme inhibitor--associated angioedema
    N J Brown
    Department of Medicine, Vanderbilt University, Nashville, Tenn 37232 6602, USA
    JAMA 278:232-3. 1997
    ..Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known...
  12. pmc Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
    J A Schoenhard
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    Hum Genet 124:479-88. 2008
    ....
  13. ncbi request reprint Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency
    N J Brown
    Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    Kidney Int 72:72-81. 2007
    ..We conclude that Ang II stimulates PAI-1 expression in part through the AT(1b) receptor in the kidney and liver. Further, norepinephrine induces PAI-1 expression in vivo with AT(1a) receptor deficiency modulating the effect...
  14. ncbi request reprint The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance
    M M Pretorius
    Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 83:122-9. 2008
    ..038) or during bradykinin (P=0.03). Increased SBP or vascular resistance may contribute to increased left ventricular mass reported previously in individuals with the BE1+9/+9 genotype...
  15. pmc Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial
    J M Balaguer
    Department of Cardiac Surgery, Vanderbilt University Medical School, Nashville, Tennessee, USA
    Clin Pharmacol Ther 93:326-34. 2013
    ..These data suggest that endogenous bradykinin contributes to t-PA generation in patients undergoing CPB, but that additional effects on plasmin generation contribute to decreased D-dimer concentrations during EACA treatment...
  16. ncbi request reprint Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition
    K Kaikita
    Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA
    Circulation 104:839-44. 2001
    ..Direct inhibition of vascular PAI-1 activity may provide a new therapeutic strategy for the prevention of arteriosclerotic cardiovascular disease...
  17. ncbi request reprint A comparison of combinatorial partitioning and linear regression for the detection of epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on plasma PAI-1 levels
    J H Moore
    Program in Human Genetics, Department of Molecular Physiology and Biophysics, 519 Light Hall, Vanderbilt University Medical School, Nashville, TN 37232 0700, USA
    Clin Genet 62:74-9. 2002
    ....
  18. ncbi request reprint Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen
    N J Brown
    Divisions of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Arterioscler Thromb Vasc Biol 21:1071-7. 2001
    ..31, P=0.014) or low (R(2)=0.37, P=0.006) salt intake. This study identifies an important gene-by-environment interaction that may influence cardiovascular morbidity and the response to pharmacological therapies that interrupt the RAAS...
  19. ncbi request reprint Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm
    T Wilsdorf
    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA
    Hypertension 37:1136-40. 2001
    ..62 for Ang-(1-7) effect]. These data do not support a role of Ang-(1-7), given at supraphysiological doses, in the regulation of human peripheral vascular resistance or fibrinolysis...
  20. ncbi request reprint Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
    J Ma
    Division of Pediatric Nephrology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    Kidney Int 69:1064-72. 2006
    ..05). Aldosterone induced cardiac hypertrophy but not fibrosis in WT and PAI-1(-/-) mice. PAI-1 contributes to aldosterone-induced glomerular injury...
  21. ncbi request reprint Angiotensin II type I receptor polymorphism in African Americans lower frequency of the C1166 variant
    J V Gainer
    Vanderbilt University Medical Center, Division of Clinical Pharmacology, Nashville, TN, USA
    Biochem Mol Biol Int 43:227-31. 1997
    ..05 +/- 0.01) and demonstrates a significantly lower frequency in African Americans compared with Caucasians (0.05 vs. 0.25, respectively, chi 2 = 30.7, p < < 0.001, 1 df)...
  22. ncbi request reprint Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia
    J S Williams
    Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Hum Hypertens 20:129-36. 2006
    ..2%, a rate that might lead to excessive false positives with random screening in comparable populations. Hyperaldosteronism, when present, is responsive to sodium restriction...
  23. ncbi request reprint The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms
    J H Moore
    Program in Human Genetics, Department of Molecular Physiology and Biophysics, 519 Light Hall, Vanderbilt University Medical School, Nashville, TN 37232 0700, USA
    Clin Genet 62:53-9. 2002
    ..This study supports the idea that interactions between the fibrinolytic and renin-angiotensin systems play an important role in the genetic architecture of plasma t-PA and PAI-1...
  24. pmc Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass
    F T Billings
    Department of Anesthesiology, Vanderbilt University Medical School, Nashville, Tennessee, USA
    Clin Pharmacol Ther 91:1065-73. 2012
    ..By contrast, neither ACE inhibition nor ARB affected the inflammatory response. ACE inhibitors and ARBs may be safely continued until the day of surgery...
  25. pmc Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
    J M Luther
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2200 Pierce Ave, 560 RRB, Nashville, TN 37232 6602, USA
    Diabetologia 54:2152-63. 2011
    ..Aldosterone concentrations increase in obesity and predict the onset of diabetes. We investigated the effects of aldosterone on glucose homeostasis and insulin secretion in vivo and in vitro...
  26. ncbi request reprint Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay
    L J Murphey
    Division of Clinical Pharmacology, Veterans Affairs Medical Center, Nashville, Tennessee 37232-6602, USA
    Anal Biochem 292:87-93. 2001
    ..This assay provides the first accurate and precise method using MS to quantify BK1-5 in human blood as a marker for the production of systemic bradykinin in humans...
  27. ncbi request reprint Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice
    M Eren
    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6300, USA
    J Thromb Haemost 1:2389-96. 2003
    ..9 kb promoter...
  28. ncbi request reprint Possible medication errors in home healthcare patients
    S Meredith
    Department of Preventive Medicine, Division of Pharmacoepidemiology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Am Geriatr Soc 49:719-24. 2001
    ..More-effective methods are needed to improve medication use in this vulnerable population...
  29. pmc Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use
    J B Byrd
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Allergy 65:1381-7. 2010
    ..One study has reported an increased incidence of ACE inhibitor-associated angioedema among transplant patients compared to published rates, while several case series report angioedema in patients taking specific immunosuppressant agents...
  30. ncbi request reprint Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans
    J V Gainer
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Am J Hypertens 13:1268-73. 2000
    ..75 v. 0.62, P = .009). Thus, this B2 receptor promoter polymorphism may represent a susceptibility marker for essential hypertension in African-Americans...
  31. ncbi request reprint Ala92 type 2 deiodinase allele increases risk for the development of hypertension
    Olga Gumieniak
    Endocrinology, Diabetes, and Hypertension Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Hypertension 49:461-6. 2007
    ..These data support an important role for genetic variation in the hypothalamic-pituitary-thyroid pathway in influencing susceptibility to hypertension...
  32. pmc Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade
    Jean Lefebvre
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    J Pharmacol Exp Ther 320:1261-7. 2007
    ..HOE-140 augmented the heart rate response to chronic valsartan (P = 0.04). These data suggest that endogenous bradykinin does not contribute significantly to the blood pressure-lowering effect of valsartan through its B(2) receptor...
  33. ncbi request reprint Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism
    James M Luther
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 48:1050-7. 2006
    ..In contrast, angiotensin II-induced oxidative stress, as measured by F(2)-isoprostanes, is mineralocorticoid receptor independent and may be pressor dependent...
  34. ncbi request reprint Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans
    Laine J Murphey
    Department of Medicine and Pharmacology, Vanderbilt University, Nashville, TN 37232 6602, USA
    J Pharmacol Exp Ther 318:1287-92. 2006
    ..By inhibiting thrombin-induced platelet aggregation without causing vasodilation, bradykinin 1-5 may provide a model for small molecule substrate-selective thrombin inhibitors...
  35. pmc Centralized oversight of physician-scientist faculty development at Vanderbilt: early outcomes
    Abigail M Brown
    Programs of Clinical and Translational Scientist Development and Biomedical Research Education and Training, Vanderbilt School of Medicine, Nashville, Tennessee 37232 6602, USA
    Acad Med 83:969-75. 2008
    ..The authors evaluate the impact of the VPSD and VCRS programs on early career outcomes of physician-scientists...
  36. ncbi request reprint Blood pressure reduction and tissue-type plasminogen activator release
    Nancy J Brown
    Hypertension 47:648-9. 2006
  37. ncbi request reprint Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Hypertension 47:441-8. 2006
    ..During angiotensin-converting enzyme inhibition, endogenous NO decreases plasminogen activator inhibitor-1 antigen and improves fibrinolytic balance in normotensive salt-replete subjects...
  38. ncbi request reprint A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass
    Mias Pretorius
    Veterans Affairs Medical Center and Department of Anesthesiology, Vanderbilt University School of Medicine, 560 Robinson Research Building, Nashville, TN 37232, USA
    Clin Pharmacol Ther 78:477-85. 2005
    ..This study tests the primary hypothesis that blocking the bradykinin B(2) receptor would attenuate protamine-related hypotension...
  39. ncbi request reprint Regression of existing glomerulosclerosis by inhibition of aldosterone
    Jean Claude Aldigier
    Department of Pathology, Vanderbilt University Medical Center, 21st and Garland Avenue, Nashville, TN 37232 2561, USA
    J Am Soc Nephrol 16:3306-14. 2005
    ..It is concluded that inhibition of aldosterone by SP not only slows development of glomerulosclerosis but also induces regression in some rats of existing glomerulosclerosis...
  40. pmc Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery
    Gregory A Fleming
    Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Circulation 118:1619-25. 2008
    ..Inotropic drugs are commonly used perioperatively to support ventricular function. This study tested the hypothesis that the use of inotropic drugs is associated with postoperative AF...
  41. ncbi request reprint Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension
    Bindu Chamarthi
    Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 92:1340-6. 2007
    ..Emerging evidence suggests a role for cortisol in essential hypertension, and preliminary reports indicate that urinary free cortisol (UFC) may be an intermediate phenotype...
  42. ncbi request reprint Aldosterone and end-organ damage
    Annis M Marney
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Clin Sci (Lond) 113:267-78. 2007
    ....
  43. pmc Association of a CYP4A11 variant and blood pressure in black men
    James V Gainer
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    J Am Soc Nephrol 19:1606-12. 2008
    ..These data support a role for renal monooxygenases and 20-hydroxyeicosatetraenoic acid in the regulation of BP and renal function in men...
  44. pmc 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Hypertension 51:1190-6. 2008
    ..17Beta-estradiol increases basal release of active t-PA in young postmenopausal women, consistent with enhanced vascular fibrinolytic function...
  45. pmc The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension
    Cheryl L Laffer
    Texas A and M Health Science Center College of Medicine, Temple, TX 76508, USA
    Hypertension 51:767-72. 2008
    ..We propose that genotype analyses with sufficient homozygous CC will establish definitive relationships among 20-HETE, salt sensitivity of blood pressure, and insulin resistance...
  46. pmc Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition
    Gary P Van Guilder
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 51:454-9. 2008
    ..In conclusion, the BDKRB2 BE1 polymorphism influences bradykinin type 2 receptor-mediated vasodilation during angiotensin-converting enzyme inhibition...
  47. doi request reprint Aldosterone and vascular inflammation
    Nancy J Brown
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Hypertension 51:161-7. 2008
  48. pmc Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema
    James Brian Byrd
    Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    Hypertension 51:141-7. 2008
    ..Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema...
  49. ncbi request reprint A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1
    Scott M Williams
    Center for Human Genetics Research, 519 Light Hall, Vanderbilt University Medical School, Nashville, TN 37232 0700, USA
    Ethn Dis 17:492-7. 2007
    ..We have initiated a large-scale population-based study to characterize the genetic architecture of plasma t-PA and PAI-1 in Blacks from Sunyani, Ghana...
  50. ncbi request reprint Functional BSND variants in essential hypertension
    Saba Sile
    Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232 0275, USA
    Am J Hypertens 20:1176-1182. 2007
    ..Sodium chloride reabsorption in the thick ascending limb (TAL) is dependent in part on the chloride channel, ClC-Kb (encoded by CLCNKB), and its accessory subunit, barttin (encoded by BSND)...
  51. ncbi request reprint Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University Medical School, Nashville, TN 37232, USA
    Circulation 116:I1-7. 2007
    ..This study tests the hypothesis that biomarkers predict the development of postoperative AF...
  52. ncbi request reprint The kallikrein-kinin system: current and future pharmacological targets
    Marie Eve Moreau
    Faculty of Pharmacy, University of Montreal, Canada
    J Pharmacol Sci 99:6-38. 2005
    ....
  53. pmc G protein-coupled receptor kinase 4 gene variants in human essential hypertension
    Robin A Felder
    Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Proc Natl Acad Sci U S A 99:3872-7. 2002
    ..These findings provide a mechanism for the D(1) receptor coupling defect in the kidney and may explain the inability of the kidney to properly excrete sodium in genetic hypertension...
  54. ncbi request reprint Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1
    Li Jun Ma
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Diabetes 53:336-46. 2004
    ..Inhibition of PAI-1 might provide a novel anti-obesity and anti-insulin resistance treatment...
  55. ncbi request reprint Loss of sodium modulation of plasma kinins in human hypertension
    Laine J Murphey
    Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Pharmacol Exp Ther 308:1046-52. 2004
    ..With hypertension, these modulating effects are diminished or lost, supporting a role for both systems in the development/maintenance of hypertension...
  56. ncbi request reprint Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function
    Marshall L Summar
    Department of Pediatrics, Division of Medical Genetics, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Hypertension 43:186-91. 2004
    ..943). These data indicate that a polymorphism in the gene encoding carbamoyl-phosphate synthetase 1 influences nitric oxide production as well as vascular smooth muscle reactivity...
  57. ncbi request reprint Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University, Nashville, Tenn, USA
    Circulation 108:3079-83. 2003
    ..Because angiotensin II stimulates PAI-1 expression, we tested the hypothesis that preoperative angiotensin-converting enzyme (ACE) inhibition decreases PAI-1 expression after CABG...
  58. ncbi request reprint Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives
    Laine J Murphey
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Free Radic Biol Med 35:711-8. 2003
    ..2 +/- 4.4 to 58.9 +/- 6.6 pg/ml, p=0.83). Acute Ang II infusion increases oxidative stress in vivo in hypertensive humans. The renin-angiotensin system may contribute to oxidative stress in human cardiovascular disease...
  59. ncbi request reprint Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1
    Pairunyar Sawathiparnich
    Divisions of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Clin Endocrinol Metab 88:3867-73. 2003
    ..2 ng/ml (9.8, 28.6), P = 0.974 vs. baseline, P < 0.05 vs. candesartan, spironolactone or furosemide alone]. This study evidences an interactive effect of endogenous Ang II and aldosterone on PAI-1 production in humans...
  60. ncbi request reprint Eplerenone: cardiovascular protection
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 107:2512-8. 2003
    ..This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity...
  61. ncbi request reprint Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 107:579-85. 2003
    ..This study tested the hypothesis that ACE inhibition increases endothelial t-PA release through endogenous bradykinin...
  62. ncbi request reprint Characterization of the CYP4A11 gene, a second CYP4A gene in humans
    Aouatef Bellamine
    Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232 0146, USA
    Arch Biochem Biophys 409:221-7. 2003
    ..RT-PCR amplification of human kidney RNA followed by restriction fragment analysis showed that CYP4A11 is the predominant isoform expressed in kidney...
  63. ncbi request reprint PAI-1 in human hypertension: relation to hypertensive groups
    Nadarajah Srikumar
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Hypertens 15:683-90. 2002
    ..Although the renin-angiotensin system and insulin resistance (IR) have been identified as major regulators of plasminogen activator inhibitor type-1 (PAI-1), their roles in hypertensive subjects is not clearly defined...
  64. ncbi request reprint Smoking impairs bradykinin-stimulated t-PA release
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 39:767-71. 2002
    ..The vascular tissue plasminogen activator response to bradykinin, but not methacholine, is impaired in smokers. Stimulated tissue plasminogen activator release may be a more sensitive measure of endothelial function than vasodilation...
  65. ncbi request reprint Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition
    Koichi Kaikita
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Mol Cell Cardiol 34:617-27. 2002
    ..While PAI-1 deficiency protects against L -NAME-induced hypertension and perivascular fibrosis, t-PA deficiency does not exacerbate the vascular pathology or hypertension...
  66. pmc An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation
    Christopher S Coffey
    Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    BMC Bioinformatics 5:49. 2004
    ..One advantage of the MDR method is that it provides an internal prediction error for validation. We summarize our use of this internal prediction error for model validation...
  67. ncbi request reprint The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1
    Marvin T Nieman
    Thromgen Inc, Ann Arbor, MI 48109 0640, USA
    J Pharmacol Exp Ther 311:492-501. 2004
    ..TH146 and MAP4-TH146 inhibit human and mouse platelet aggregation and mouse thrombosis. Analogs of RPPGF are model compounds to develop PAR1 activation antagonists as well as direct inhibitors to thrombin and factor VIIa...
  68. ncbi request reprint Established and emerging plasma biomarkers in the prediction of first atherothrombotic events
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, Mass 02115, USA
    Circulation 109:IV6-19. 2004
  69. ncbi request reprint Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men
    Mias Pretorius
    Veterans Affairs Medical Center, Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Arterioscler Thromb Vasc Biol 25:2435-40. 2005
    ..Angiotensin-converting enzyme inhibition (ACEI) increases vascular tissue plasminogen activator (t-PA) release through endogenous bradykinin (BK). We tested the hypothesis that gender influences the effect of ACEI on t-PA release...
  70. ncbi request reprint Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance
    Ji Ma
    Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA
    Hypertension 46:313-20. 2005
    ....
  71. ncbi request reprint Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension
    Lorraine M King
    Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    Pharmacogenet Genomics 15:7-13. 2005
    ..Confirmation of these findings in additional populations is warranted...
  72. ncbi request reprint Aldosterone and end-organ damage
    Nancy J Brown
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    Curr Opin Nephrol Hypertens 14:235-41. 2005
    ....
  73. ncbi request reprint Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension
    James V Gainer
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical School, Nashville, Tenn 37232 0146, USA
    Circulation 111:63-9. 2005
    ..We combined molecular and biochemical approaches to identify a functional variant of the CYP4A11 20-HETE synthase and determine its association with hypertensive status in 2 independent human populations...
  74. ncbi request reprint Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling
    Alec D Weisberg
    Department of Medicine, Divisions of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Arterioscler Thromb Vasc Biol 25:365-71. 2005
    ....
  75. ncbi request reprint Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass
    Mias Pretorius
    Veterans Affairs Medical Center and Department of Anesthesiology, and Division of Cardiovascular Medicine
    Clin Pharmacol Ther 76:379-87. 2004
    ..This study tested the hypothesis that angiotensin-converting enzyme (ACE) inhibitors potentiate activation of the kallikrein-kinin system during cardiopulmonary bypass (CPB)...
  76. ncbi request reprint Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Medicine, Vanerbilt University Medical Center, Nashville, Tennessee, USA
    Circulation 105:304-9. 2002
    ..001) and a significant interactive effect of 4G/5G genotype and treatment, such that genotype influenced the change in PAI-1 during ramipril (P=0.011) or combined therapy (P=0.006) but not during estrogens (P=0.715)...
  77. ncbi request reprint Uric acid and the state of the intrarenal renin-angiotensin system in humans
    Todd S Perlstein
    Endocrinology, Diabetes and Hypertension Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Kidney Int 66:1465-70. 2004
    ..The renal vascular response to exogenous angiotensin II (Ang II) provides an indirect measure of intrarenal RAS activity. We tested the hypothesis that the serum uric acid concentration predicts the renal vascular response to Ang II...
  78. ncbi request reprint Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans
    Pairunyar Sawathiparnich
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Clin Endocrinol Metab 87:448-52. 2002
    ..57; P = 0.0003); however, treatment with spironolactone abolished this correlation (r(2) = 0.13; P = 0.33). This study provides evidence that endogenous aldosterone influences PAI-1 production in humans...
  79. ncbi request reprint NO synthase inhibition increases aldosterone in humans
    James A S Muldowney
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 44:739-45. 2004
    ..2 . [potassium]-28.9; r2=0.609; P=0.008) but not during vehicle (P=0.313). These data suggest that endogenous NO modulates aldosterone synthesis in humans...
  80. ncbi request reprint Thyroid function and blood pressure homeostasis in euthyroid subjects
    Olga Gumieniak
    Endocrinology, Diabetes and Hypertension Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Avenue, RFB 2, Boston, MA 02115, USA
    J Clin Endocrinol Metab 89:3455-61. 2004
    ..These data show that the influence of thyroid function on blood pressure homeostasis extends into euthyroid range and likely reflects the action of thyroid hormone on peripheral vasculature...
  81. ncbi request reprint Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema
    Jean Lefebvre
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Hypertension 39:460-4. 2002
    ..With respect to APP activity, there was no difference between groups. These results suggest that DPPIV activity is depressed in individuals with hypertension during acute ACEI-associated angioedema...
  82. pmc A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors
    Qing Ling Duan
    Centre de Recherche du CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Am J Hum Genet 77:617-26. 2005
    ..0364). In conclusion, our findings provide supporting evidence that the C-2399A variant in XPNPEP2 is associated with reduced APP activity and a higher incidence of AE-ACEi...
  83. ncbi request reprint Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin
    David A Rosenbaum
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn, USA
    Arterioscler Thromb Vasc Biol 22:1023-8. 2002
    ..037). These data suggest that the BK-dependent alterations in vascular fibrinolytic function are preserved in black Americans compared with white Americans...
  84. ncbi request reprint Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema
    James Brian Byrd
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Allergy Clin Immunol 120:403-8. 2007
    ..ACE and DPPIV degrade substance P, an edema-forming peptide. The contribution of impaired degradation of substance P by DPPIV to the pathogenesis of ACE inhibitor-associated angioedema is unknown...
  85. ncbi request reprint Angiotensin-converting enzyme inhibitor-associated angioedema
    James Brian Byrd
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 560 Robinson Research Building, Nashville, TN 37232 6602, USA
    Immunol Allergy Clin North Am 26:725-37. 2006
    ..Defective degradation of vasoactive peptide substrates of ACE, such as bradykinin or substance P, may contribute via non-ACE pathways to the pathogenesis of ACE inhibitor-associated angioedema...
  86. ncbi request reprint Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension
    Luminita Pojoga
    Brigham and Women s Hospital, Division of Endocrinology, Diabetes, and Hypertension, 221 Longwood Ave, Boston, MA 02115, USA
    Hypertension 48:892-900. 2006
    ..Importantly, this association could only be detected with an intermediate and not a distant phenotype...
  87. ncbi request reprint Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid
    James A S Muldowney
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6300, USA
    Thromb Haemost 97:263-71. 2007
    ..These studies suggest that thrombin-stimulated t-PA release is Galphaq-, PLC-beta-, IP3-, and 5,6-EET-dependent while being prostacyclin-, NO- and K+ channel-independent in HMECs...